Lista de obras - Shanu Modi - Dominio Público Uruguay

A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer

artículo científico publicado en 2006

A Phase I study of DLYE5953A, an anti-LY6E antibody covalently linked to monomethyl auristatin E, in patients with refractory solid tumors

artículo científico publicado en 2020

A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer

artículo científico publicado en 2015

A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer

artículo científico publicado en 2011

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

artículo científico publicado en 2013

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.

artículo científico publicado en 2012

A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors

artículo científico publicado en 2012

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer

artículo científico publicado en 2011

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

artículo científico publicado en 2017

A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer

artículo científico publicado en 2013

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

artículo científico publicado en 2012

A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

artículo científico publicado en 2005

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

artículo científico publicado en 2005

Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series

artículo científico publicado en 2014

Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers

artículo científico publicado en 2012

An update on epidermal growth factor receptor inhibitors

artículo científico publicado en 2002

Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer

artículo científico publicado en 2011

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

artículo científico publicado en 2007

First-in-Human Trial of Epichaperome-Targeted Positron Emission Tomography in Cancer Patients

scientific article published on 04 May 2020

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer

artículo científico publicado en 2012

Ganetespib: research and clinical development

artículo científico publicado en 2015

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

artículo científico publicado en 2011

HSP90 inhibitors for cancer therapy and overcoming drug resistance

artículo científico publicado en 2012

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions

artículo científico publicado en 2014

Immunomodulatory Activity of a Colony-Stimulating Factor-1 Receptor Inhibitor in Patients With Advanced Refractory Breast or Prostate Cancer: A Phase 1 Study

artículo científico publicado en 2020

Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane

artículo científico publicado en 2005

Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer

scientific article published on 26 March 2013

Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results

artículo científico publicado en 2010

Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience

artículo científico publicado en 2017

Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer

scientific article published on 30 September 2020

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

artículo científico publicado en 2016

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

artículo científico publicado en 2010

Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

artículo científico publicado en 2014

Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer

artículo científico

Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer.

scientific article published on December 2013

Preoperative chemotherapy for breast cancer: miracle or mirage?

artículo científico publicado en 2007

Prospective Exploratory Analysis of the Association Between Tumor Response, Quality of Life, and Expenditures Among Patients Receiving Paclitaxel Monotherapy for Refractory Metastatic Breast Cancer

article

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update

artículo científico publicado en 2018

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

artículo científico publicado en 2014

Single-agent gemcitabine in the treatment of advanced breast cancer.

artículo científico publicado en 2004

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update

scientific article published on 25 June 2018

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline

artículo científico

Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?

artículo científico publicado en 2011

Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions

artículo científico publicado en 2016

The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation

artículo científico publicado en 2015

The heat shock protein 90 chaperone complex: an evolving therapeutic target.

scientific article published on September 2008

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

article published in 2019

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study

artículo científico publicado en 2019

Lista de obras de Shanu Modi

A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer

A Phase I study of DLYE5953A, an anti-LY6E antibody covalently linked to monomethyl auristatin E, in patients with refractory solid tumors

A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer

A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.

A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series

Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers

An update on epidermal growth factor receptor inhibitors

Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

First-in-Human Trial of Epichaperome-Targeted Positron Emission Tomography in Cancer Patients

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer

Ganetespib: research and clinical development

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

HSP90 inhibitors for cancer therapy and overcoming drug resistance

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions

Immunomodulatory Activity of a Colony-Stimulating Factor-1 Receptor Inhibitor in Patients With Advanced Refractory Breast or Prostate Cancer: A Phase 1 Study

Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane

Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer

Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results

Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience

Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer

Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer.

Preoperative chemotherapy for breast cancer: miracle or mirage?

Prospective Exploratory Analysis of the Association Between Tumor Response, Quality of Life, and Expenditures Among Patients Receiving Paclitaxel Monotherapy for Refractory Metastatic Breast Cancer

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

Single-agent gemcitabine in the treatment of advanced breast cancer.

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline

Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?

Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions

The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation

The heat shock protein 90 chaperone complex: an evolving therapeutic target.

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study